Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 3673-3677
10.1182/blood-2022-157583